Genfit S.A. (EPA:GNFT – Get Free Report)’s share price rose 1.1% during mid-day trading on Wednesday . The company traded as high as €3.28 ($3.52) and last traded at €3.26 ($3.50). Approximately 59,517 shares were traded during trading, The stock had previously closed at €3.22 ($3.46).
Genfit Stock Performance
The business’s 50 day simple moving average is €3.38 and its 200-day simple moving average is €3.28.
Genfit Company Profile
Genfit SA, a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia.
Read More
- Five stocks we like better than Genfit
- What Are Growth Stocks and Investing in Them
- What is a Bull Market? Key Information about Bull Markets
- What is the Dogs of the Dow Strategy? Overview and Examples
- Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
- How to Use the MarketBeat Excel Dividend Calculator
- Dave & Buster’s Stock Value Is Unleashed, Not Too Late To Get In
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
